Acadian Asset Management LLC Has $954,000 Stock Holdings in Genmab A/S (NASDAQ:GMAB)

Acadian Asset Management LLC raised its holdings in shares of Genmab A/S (NASDAQ:GMAB - Free Report) by 360.8% in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 38,010 shares of the company's stock after purchasing an additional 29,762 shares during the period. Acadian Asset Management LLC's holdings in Genmab A/S were worth $954,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently modified their holdings of the company. Russell Investments Group Ltd. boosted its holdings in shares of Genmab A/S by 137.7% in the 1st quarter. Russell Investments Group Ltd. now owns 939 shares of the company's stock valued at $28,000 after buying an additional 544 shares during the period. GAMMA Investing LLC lifted its holdings in Genmab A/S by 194.0% in the first quarter. GAMMA Investing LLC now owns 1,135 shares of the company's stock worth $34,000 after acquiring an additional 749 shares during the last quarter. Allspring Global Investments Holdings LLC acquired a new position in Genmab A/S in the first quarter valued at approximately $43,000. Principal Securities Inc. bought a new position in shares of Genmab A/S during the fourth quarter valued at approximately $77,000. Finally, Barometer Capital Management Inc. acquired a new stake in shares of Genmab A/S during the 4th quarter worth approximately $121,000. 7.07% of the stock is owned by institutional investors and hedge funds.

Genmab A/S Price Performance

Shares of Genmab A/S stock traded down $0.15 on Tuesday, hitting $26.43. The company had a trading volume of 321,098 shares, compared to its average volume of 570,873. Genmab A/S has a 52 week low of $24.53 and a 52 week high of $37.97. The company has a market cap of $17.48 billion, a PE ratio of 22.10, a PEG ratio of 0.81 and a beta of 0.99. The business has a 50-day simple moving average of $27.27 and a 200-day simple moving average of $28.06.

Genmab A/S (NASDAQ:GMAB - Get Free Report) last posted its quarterly earnings data on Thursday, August 8th. The company reported $0.22 EPS for the quarter, missing analysts' consensus estimates of $0.29 by ($0.07). The firm had revenue of $779.50 million during the quarter, compared to the consensus estimate of $734.60 million. Genmab A/S had a return on equity of 17.48% and a net margin of 29.06%. On average, equities research analysts predict that Genmab A/S will post 1.27 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research analysts recently issued reports on the company. Morgan Stanley restated an "equal weight" rating and set a $31.00 price objective on shares of Genmab A/S in a research report on Wednesday, September 11th. HC Wainwright restated a "buy" rating and set a $50.00 price target on shares of Genmab A/S in a research report on Friday. JPMorgan Chase & Co. reiterated a "neutral" rating on shares of Genmab A/S in a research report on Tuesday, August 20th. BTIG Research upped their target price on shares of Genmab A/S from $46.00 to $47.00 and gave the stock a "buy" rating in a research report on Thursday, June 27th. Finally, Royal Bank of Canada upgraded shares of Genmab A/S from a "sector perform" rating to an "outperform" rating in a research note on Monday, July 15th. Two equities research analysts have rated the stock with a sell rating, three have given a hold rating and eight have given a buy rating to the company's stock. According to MarketBeat, the company currently has an average rating of "Hold" and a consensus price target of $45.20.

Genmab A/S Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.